Fig. 2 | Scientific Reports

Fig. 2

From: Cost-effectiveness of polatuzumab vedotin plus chemoimmunotherapy for untreated diffuse large B-cell lymphoma in China

Fig. 2

Tornado diagrams of one-way sensitivity analyses of Pola-R-CHP vs. R-CHOP. Abbreviations: ICER, incremental cost-effectiveness ratios; PFS, progressionfree survival; PD, progressive disease; Pola-R-CHP, polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Back to article page